The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
DyslipidemiaTransplants
Interventions
DRUG

Ezetimibe

Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.

Trial Locations (1)

1000

University Medical Center Ljubljana, Ljubljana

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER

NCT02103049 - The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients | Biotech Hunter | Biotech Hunter